DTxPharma Revenue and Competitors
Estimated Revenue & Valuation
- DTxPharma's estimated annual revenue is currently $5.1M per year.
- DTxPharma's estimated revenue per employee is $77,500
- DTxPharma's total funding is $113.6M.
Employee Data
- DTxPharma has 66 Employees.
- DTxPharma grew their employee count by 20% last year.
DTxPharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, DMPK | Reveal Email/Phone |
2 | Associate Director | Reveal Email/Phone |
3 | Director Operations | Reveal Email/Phone |
4 | Sr. Director, CMC & Process Chemistry | Reveal Email/Phone |
5 | Chief Scientific Officer | Reveal Email/Phone |
6 | Director Bioanalytical and DMPK | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Chief Operating Officer | Reveal Email/Phone |
9 | Chief Medical Officer | Reveal Email/Phone |
10 | Associate Director Oligonucleotide Chemistry | Reveal Email/Phone |
DTxPharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4096.4M | 10837 | 2% | N/A | N/A |
What Is DTxPharma?
DTx Pharma is a San Diego based startup with a novel technology for delivery of RNA medicines.
keywords:N/A
$113.6M
Total Funding
66
Number of Employees
$5.1M
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
DTxPharma News
SAN DIEGO, April 7, 2021 /PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that Arthur T. Suckow, Ph.D., Chief Executive Officer, will participate in virtual one-on-one m ...
Photo courtesy of DTx Pharma. In May 2020, the biotech expanded its footprint into a new 14,000 square foot lab and office space in Sorrento Valley. San Diego-based DTx Pharma, a biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, has raised a $1 ...
DTx Pharma, Inc., a San Diego, CA-based biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, completed a $100m Series B financing. The round was led by RA Capital Management with participation from new investors Access Biotechnology, Surveyor Capi ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15.5M | 66 | 25% | $12M |
#2 | $24M | 66 | -4% | N/A |
#3 | $8.3M | 66 | N/A | N/A |
#4 | $8.6M | 66 | N/A | N/A |
#5 | $16.6M | 66 | N/A | N/A |